-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Monopar Therapeutics, Raises Price Target to $128

Benzinga·08/13/2026 14:21:55
Listen to the news
Barclays analyst Etzer Darout maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $125 to $128.